Patents Represented by Attorney, Agent or Law Firm Robert T. Ronau
-
Patent number: 6306875Abstract: This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintanence of skin thickness, metabolic homeostasis or renal homeostasis.Type: GrantFiled: June 13, 2000Date of Patent: October 23, 2001Assignee: Pfizer Inc.Inventors: Philip A Carpino, Paul A DaSilva-Jardine, Bruce A Lefker, John A Ragan
-
Patent number: 6284773Abstract: This invention is directed to pharmaceutical combination compositions and methods comprising (−)-cis-6-phenyl-5-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl)-5,6,7,8-tetrahydronaphthalene-2-ol or a pharmaceutically acceptable salt thereof and PGE2 or a pharmaceutically acceptable salt thereof, methods of using such compositions and kits containing such compositions. The compositions are useful for treating musculoskeletal frailty, including osteoporosis, osteoporotic fracture, low bone mass and frailty.Type: GrantFiled: July 14, 1999Date of Patent: September 4, 2001Assignee: Pfizer Inc.Inventors: HuaZhu Ke, David D. Thompson
-
Patent number: 6278000Abstract: This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintanence of skin thickness, metabolic homeostasis or renal homeostasis.Type: GrantFiled: December 22, 1999Date of Patent: August 21, 2001Assignee: Pfizer Inc.Inventors: Philip A Carpino, Paul A DaSilva-Jardine, Bruce A Lefker, John A Ragan
-
Patent number: 6262092Abstract: This invention relates to a mutual salt of amlodipine and atorvastatin, pharmaceutical compositions thereof and methods of treating angina pectoris, atherosclerosis and combined hypertension and hyperlipidemia in mammals with such a mutual salt and compositions. This invention also relates to methods of managing cardiac risk in a mammal presenting with symptoms of cardiac risk, including humans by administering such a mutual salt and compositions.Type: GrantFiled: May 24, 2000Date of Patent: July 17, 2001Assignee: Pfizer Inc.Inventors: George Chang, Ernest S. Hamanaka
-
Patent number: 6258827Abstract: This invention relates to a method of treating Parkinson's Disease whereby a mammal suffering from Parkinson's Disease is treated with a combination of a forebrain selective NMDA antagonist and a compound which is capable of increasing the excitatory feedback from the ventral lateral nucleus of the thalamus into the cortex. This invention also relates to pharmaceutical compositions containing the synergistic combination.Type: GrantFiled: October 10, 1997Date of Patent: July 10, 2001Assignee: Pfizer Inc.Inventors: Bertrand L. Chenard, Frank S. Menniti
-
Patent number: 6251902Abstract: This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis and/or frailty, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintenance of skin thickness, metabolic homeostasis or renal homeostasis.Type: GrantFiled: September 8, 1999Date of Patent: June 26, 2001Assignee: Pfizer Inc.Inventors: Philip Albert Carpino, David Andrew Griffith, Bruce Allen Lefker
-
Patent number: 6174710Abstract: Spirolaxine, the compound of formula (I) wherein R is H, and the novel compounds of formula (I) wherein R is (C1-C6)alkyl or CH3(CH2)nCO and n is 1, 2, 3 or 4 are useful in treating gastroduodenal diseases such as gastric ulcers, duodenal ulcers and gastric cancer caused by Helicobacter pylori. Spirolaxine and spirolaxine methyl ether are isolated from the fermentation of Sporotrichum pruinosum ATCC 74278. Spirolaxine and the compounds of formula (I) are also useful in combination with H2 antagonist colloidal bismuth subcitrate and other antibiotics.Type: GrantFiled: January 16, 1997Date of Patent: January 16, 2001Assignee: Pfizer Inc.Inventors: Mark A. Guadliana, Liang H. Huang, Takushi Kaneko, Paul C. Watts
-
Patent number: 6132774Abstract: This invention is directed to pharmaceutical combination compositions and methods comprising (-)-cis-6-phenyl-5-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl)-5,6,7,8-tetrahydr onaphthalene-2-ol or a pharmaceutically acceptable salt thereof and parathyroid hormone or a biologically active fragment thereof, methods of using such compositions and kits containing such compositions. The compositions are useful for treating musculoskeletal frailty, including osteoporosis, osteoporotic fracture, low bone mass and frailty.Type: GrantFiled: November 15, 1999Date of Patent: October 17, 2000Assignee: Pfizer Inc.Inventors: HuaZhu Ke, David D. Thompson
-
Patent number: 6130241Abstract: The invention provides an insect- or acarid-repellent formulation comprising a compound of formula (I), wherein R represents straight or branched chain C.sub.2-10 alkyl, straight or branched chain C.sub.2-10 alkenyl, or straight or branched chain C.sub.2-10 alkynyl, which groups are optionally substituted by one or more groups selected from halogen, C.sub.4-8 cycloalkyl and C.sub.4-8 cycloalkenyl; and a suitable adjuvant, diluent or carrier.Type: GrantFiled: March 10, 1999Date of Patent: October 10, 2000Assignee: Pfizer Inc.Inventor: Darren John Schulz
-
Patent number: 6124314Abstract: This invention relates to prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.Type: GrantFiled: September 28, 1998Date of Patent: September 26, 2000Assignee: Pfizer Inc.Inventors: Kimberly O. Cameron, Bruce A. Lefker, Robert L. Rosati
-
Patent number: 6124457Abstract: The instant invention relates to intermediates of Formula II, ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are as defined in the specification, and to processes for preparing such intermediates. This invention also relates to processes for preparing compounds of Formula III, ##STR2## and enantiomers thereof, wherein R.sup.2, R.sup.3 and R.sup.4 are as defined in the specification. Compounds of Formula II and Formula III are intermediates in the preparation of a potent .beta..sub.3 adrenergic receptor agonist. The instant invention also relates to processes for preparing the .beta..sub.3 adrenergic receptor agonist using the compounds of Formula II and Formula III.Type: GrantFiled: January 20, 2000Date of Patent: September 26, 2000Assignee: Pfizer Inc.Inventors: Keith M. DeVries, Jeffrey W. Raggon, Ravi M. Shanker, Frank J. Urban, Brian C. Vanderplas
-
Patent number: 6124264Type: GrantFiled: March 1, 1999Date of Patent: September 26, 2000Assignee: Pfizer Inc.Inventors: Philip A Carpino, Paul A DaSilva-Jardine, Bruce A Lefker, John A Ragan
-
Patent number: 6110932Abstract: This invention is directed to compounds of the formula ##STR1## and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating would healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintanence of skin thickness, metabolic homeostasis or renal homeostasis.Type: GrantFiled: March 1, 1999Date of Patent: August 29, 2000Assignee: Pfizer Inc.Inventors: Philip A Carpino, Paul A DaSilva-Jardine, Bruce A Lefker, John A Ragan
-
Patent number: 6107306Abstract: This invention is directed to compounds of the formula ##STR1## and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintanence of skin thickness, metabolic homeostasis or renal homeostasis.Type: GrantFiled: March 1, 1999Date of Patent: August 22, 2000Assignee: Pfizer Inc.Inventors: Philip A Carpino, Paul A DaSilva-Jardine, Bruce A Lefker, John A Ragan
-
Patent number: 6090942Abstract: The instant invention relates to intermediates of Formula II, ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are as defined in the specification, and to processes for preparing such intermediates. This invention also relates to processes for preparing compounds of Formula III, ##STR2## and enantiomers thereof, wherein R.sup.2, R.sup.3 and R.sup.4 are as defined in the specification. Compounds of Formula II and Formula III are intermediates in the preparation of a potent .beta..sub.3 adrenergic receptor agonist. The instant invention also relates to processes for preparing the .beta..sub.3 adrenergic receptor agonist using the compounds of Formula II and Formula III.Type: GrantFiled: September 29, 1999Date of Patent: July 18, 2000Assignee: Pfizer Inc.Inventors: Keith M. DeVries, Jeffrey W. Raggon, Ravi M. Shanker, Frank J. Urban, Brian C. Vanderplas
-
Patent number: 6074855Abstract: Processes for preparing spirolaxine and spirolaxine methyl ether, the compounds of formulas (I) and (II) respectively, ##STR1## comprising fermenting fungi selected from the group consisting of Sporotrichum pruinosum FD 29585, ATCC 74327; Sporotrichum pruinosum FD 29454, ATCC 74329; Sporotrichun pruinosum FD 29586, ATCC 74328; and Phanerochaete chrysosporiun LN 3576, ATCC 74326. This invention also relates to a process for preparing spirolaxine comprising fermenting Sporotrichum pruinosum FD 29458, ATCC 74330.Type: GrantFiled: August 14, 1997Date of Patent: June 13, 2000Assignee: Pfizer Inc.Inventors: Mark A. Guadliana, Liang H. Huang, Takushi Kaneko
-
Patent number: 6046213Abstract: This invention relates to compounds of formula (I), or pharmaceutically acceptable acid addition salts thereof, wherein: (a) R.sup.2 and R.sup.5 are taken separately and R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are each independently hydrogen, (C.sub.1 -C.sub.6) alkyl, halo, CF.sub.3, OH or OR.sup.7 and R.sup.5 is methyl or ethyl; or (b) R.sup.2 and R.sup.5 are taken together, forming a chroman-4-ol ring, and R.sup.1, R.sup.3 and R.sup.4 are each independently hydrogen, (C.sub.1 -C.sub.6) alkyl, halo, CF.sub.3, OH or OR.sup.7 ; and R.sup.6 is a substituted piperidinyl, pyrrolidinyl or 8-azabicyclo(3.2.1)octanyl derivative; provided that (a) when R.sup.2 and R.sup.5 are taken separately, at least one of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 is not hydrogen; and (b) when R.sup.2 and R.sup.5 are taken together, at least one of R.sup.1, R.sup.3 and R.sup.Type: GrantFiled: February 13, 1997Date of Patent: April 4, 2000Assignee: Pfizer Inc.Inventors: Bertrand L. Chenard, Todd W. Butler
-
Patent number: 6037505Abstract: The anantoselective borane reduction of prochiral ketones to optically pure alcohols is effectively achieved by performing the reduction in the precence of catalytic amounts of the new and valuable oxazaborolidine compounds of formulas (I) and (II). The compounds of formulas (I) and (II) may be isolated and purified prior to use in the reduction reactions or the compounds of formulas (I) and (II) may be generated in situ.Type: GrantFiled: April 26, 1999Date of Patent: March 14, 2000Assignee: Pfizer Inc.Inventor: George Joseph Quallich
-
Patent number: 6034107Abstract: The present invention provides novel 5-substituted picolinic acid compounds of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein R.sup.1 and R.sup.2 are independently H, C.sub.2 -C.sub.6 acyl or halo-substituted benzoyl; and R.sup.3 is --C(O)O--C.sub.1 -C.sub.6 alkyl, C(O)OH, CN, CONH.sub.2, CONHCH.sub.3, CON(CH.sub.3).sub.2, 1-methyltetrazole or 2-methyltetrazole, with the proviso that when R.sub.2 is acetyl and R.sup.3 is methoxycarbonyl, R.sup.1 is not H; and that when R.sup.3 is CN, CONH.sub.2, CONHCH.sub.3, CON(CH.sub.3).sub.2, 1-methyltetrazole or 2-methyltetrazole, R.sup.1 and R.sup.2 are H.The present invention also relates to a pharmaceutical composition comprising compound of the present invention, which is useful in the treatment of IL-1 and TNF mediated diseases or the like.The present invention further relates to a process for producing the compounds of the formula (I).Type: GrantFiled: October 26, 1998Date of Patent: March 7, 2000Assignee: Pfizer Inc.Inventors: Hideo Hirai, Katsuomi Ichikawa, Nakao Kojima, Hiroyuki Nishida, Kunio Satake, Nobuji Yoshikawa
-
Patent number: 6014212Abstract: A method of and apparatus for spectrophotometrically analyzing a tablet by NIR transmission measurements includes a tablet holder 1 having a recess 5 within which a tablet 20 is located. A probe 40 is applied to the tablet 20 to direct an NIR beam 45 to and through the tablet for sensing at a detector 32 from which measurements characteristics of the tablet are analyzed. The recess 5 accommodates the tablet 20 as a close, possibly complementary fit. The tablet is clamped in the recess 5 by a spring loaded rod 8 to ensure that the tablet is located and retained at a predetermined position in the recess 5 relative to an aperture 7 through which the transmitted beam is directed to the detector 32. Preferably the tablet 20 is subjected to clamping forces applied by two spring loaded clamping rods disposed substantially perpendicularly relative to each other in the tablet holder.Type: GrantFiled: August 4, 1998Date of Patent: January 11, 2000Assignee: Pfizer Inc.Inventors: Stephen Victor Hammond, Tony Graham Axon, Rachel Brown